With his group and collaborators, Chris aims to beat drug resistance in cancer using systems biology methods to develop combination therapies. They are also developing the next generation cBioPortal for cancer research and therapy, obtaining biomolecular structures and functional interactions on a large scale using evolutionary information, and adapting machine learning methods to mine millions of genomes. He is collaborating with groups in Denmark and the US to apply AI to longitudinal health records to identify patients at high risk for pancreatic and ovarian cancer and collaborates with clinicians in the design of effective affordable surveillance program aiming at the early detection of cancer.